Albuterol

Overview

It is most commonly utilized for the rapid relief of bronchospasm and acute airway obstruction, particularly in cats and horses, with more limited use in dogs.

Albuterol is available in multiple dosage forms, including oral preparations and inhaled formulations (metered-dose inhalers and nebulized solutions). Inhaled delivery is preferred when possible, as it provides rapid onset of action with minimal systemic absorption and fewer adverse effects compared with oral administration.

Mechanism of Action (MOA): Albuterol selectively stimulates beta-2 adrenergic receptors located on bronchial smooth muscle, leading to smooth muscle relaxation, bronchodilation, and reduced airway resistance. At therapeutic doses, beta-1 cardiac receptor stimulation is minimal; however, at higher doses or systemic exposure, beta-1 effects may occur, resulting in tachycardia and increased myocardial contractility. Beta-2 agonism also promotes intracellular shifting of potassium, which may cause transient hypokalemia.

Pharmacokinetics: After oral administration, albuterol is well absorbed; after nebulization, less than 20% of the dose is systemically absorbed. Onset of effect is approximately 5 minutes after oral inhalation and 30 minutes after oral administration. Duration of effect is 3-6 hours after nebulization and up to 12 hours after oral administration. Albuterol does not cross the blood-brain barrier but does cross the placenta. The drug is extensively hepatically metabolized to the inactive metabolite albuterol 4′-O-sulfate. Oral serum half-life in humans is 2.7-5 hours. In horses, racemic albuterol produces bronchodilation for 30-60 minutes; the R-form (levalbuterol) provides comparable bronchodilation lasting twice as long (120 minutes).

Indications

Albuterol is used primarily for its bronchodilatory effects to relieve acute bronchospasm and improve airflow in animals with reversible lower airway obstruction. Its clinical use varies by species, with the greatest utility in cats.

• Acute bronchospasm: Acute bronchospasm: Used to rapidly relieve bronchoconstriction in cats and horses by relaxing bronchial smooth muscle and reducing airway resistance.
• Feline asthma (rescue therapy): Feline asthma (rescue therapy): In cats, inhaled albuterol is commonly used for short-term, intermittent treatment of acute asthma exacerbations. It should be reserved for rescue use and not for long-term control of airway inflammation.
• Bronchoconstriction in dogs (limited use): Bronchoconstriction in dogs (limited use): Although true bronchoconstriction is uncommon in dogs, albuterol may be beneficial in select cases where bronchospasm is present.
• Procedure-related bronchoconstriction: Procedure-related bronchoconstriction: Used prior to bronchoscopy, bronchoalveolar lavage (BAL), or endotracheal wash in cats to reduce procedure-induced bronchospasm.

Dosage (Reference)

Dog

True bronchoconstriction is uncommon in dogs; therefore, albuterol use is considered extra-label and should be reserved for confirmed or suspected bronchospasm. Start with the lowest effective dose and monitor closely for cardiovascular or CNS adverse effects.

Cat

In cats, albuterol is most commonly administered via inhalation for rapid relief of acute bronchospasm associated with feline asthma. It should be used as a rescue medication only and not for long-term management.

Warnings & Precautions

Albuterol is a beta-adrenergic agonist with primary effects on bronchial smooth muscle, but systemic beta-adrenergic stimulation may occur, particularly at higher doses or with oral administration. Careful patient selection and monitoring are essential.

• Cardiovascular disease: Cardiovascular disease: Use with caution in patients with cardiac dysrhythmias, cardiomyopathy, or other cardiac dysfunction, as tachycardia and arrhythmias may occur.
• Hypertension: Hypertension: Beta-adrenergic stimulation may exacerbate hypertension; monitor blood pressure when clinically indicated.
• Seizure disorders: Seizure disorders: CNS stimulation may lower seizure threshold; use cautiously in patients with a history of seizures.
• Hyperthyroidism: Hyperthyroidism: Sensitivity to sympathomimetic effects may be increased; adverse cardiovascular effects are more likely.
• Diabetes mellitus: Diabetes mellitus: Albuterol may cause transient hyperglycemia; monitor glycemic control in diabetic patients.
• Hypokalemia: Hypokalemia: Beta-agonists promote intracellular potassium shifts, potentially causing transient hypokalemia, especially with high doses or concurrent diuretic therapy.
• Pregnancy: Pregnancy: Albuterol crosses the placenta and is teratogenic (cleft palate) in rodents at doses lower than those used clinically in humans. Use only when potential benefits outweigh risks. Late-pregnancy use may inhibit uterine contractions and delay pre-term labor (oral administration). Fetal hyperglycemia and tachycardia may occur.
• Lactation: Lactation: It is not known whether albuterol is excreted in milk. Use with caution in nursing animals.
• Long-term use in cats: Long-term use in cats: Regular (racemic) albuterol may increase airway inflammation; restrict use to acute rescue therapy rather than chronic management.
• Levalbuterol (R-isomer): The R-isomer of albuterol is the active bronchodilator; the S-isomer is associated with adverse effects (including airway inflammation in cats). Levalbuterol contains only the R-isomer and produces less airway inflammation than racemic albuterol in cats; consider it if more than occasional rescue use is needed.
• Species sensitivity: Species sensitivity: Horses receiving high inhaled doses may develop sweating, excitement, muscle twitching, or hypokalemia; monitor closely.
• Product confusion: Product confusion: Do not confuse albuterol with atenolol or salbutamol with salmeterol, as dosing errors may result in severe adverse effects.

Drug Interactions

Drug interactions with albuterol are primarily related to additive cardiovascular stimulation, effects on serum potassium, or antagonism of beta-adrenergic activity. Most clinically relevant interactions are more likely with oral administration rather than inhalation.

• Beta-adrenergic blockers (e.g., atenolol, propranolol): Beta-adrenergic blockers (e.g., atenolol, propranolol): May antagonize the bronchodilatory effects of albuterol and reduce clinical efficacy.
• Digoxin: Digoxin: Albuterol may increase the risk of cardiac arrhythmias, particularly in patients with underlying heart disease.
• Diuretics: Diuretics: Concurrent use may exacerbate albuterol-induced hypokalemia, increasing the risk of weakness or cardiac arrhythmias.
• Inhaled anesthetics (e.g., isoflurane): Inhaled anesthetics (e.g., isoflurane): May increase susceptibility to ventricular arrhythmias, especially in patients with preexisting cardiac disease.
• Monoamine oxidase inhibitors (MAOIs; e.g., amitraz, selegiline, linezolid): Monoamine oxidase inhibitors (MAOIs; e.g., amitraz, selegiline, linezolid): May potentiate the vascular and cardiovascular effects of albuterol.
• Succinylcholine: Concurrent administration may enhance neuromuscular blockade.
• Other sympathomimetic amines (e.g., phenylpropanolamine): Other sympathomimetic amines (e.g., phenylpropanolamine): Additive cardiovascular stimulation may occur, increasing the risk of tachycardia and hypertension.
• Theophylline: Theophylline: Albuterol may decrease theophylline concentrations; combined use may increase CNS stimulation, hypokalemia, and the risk of cardiac arrhythmias.
• Tricyclic antidepressants (e.g., amitriptyline, clomipramine): Tricyclic antidepressants (e.g., amitriptyline, clomipramine): May potentiate the vascular effects of albuterol.
• Corticosteroids: Concurrent systemic corticosteroid use may worsen albuterol-induced hypokalemia; inhaled corticosteroids are the recommended maintenance partner and pose low interaction risk via inhalation.

Side Effects & Overdose

Side Effects

Most adverse effects of albuterol are dose-dependent and consistent with beta-adrenergic stimulation. These effects are generally transient and mild, but may be more pronounced with systemic (oral or injectable) administration compared to inhalation.

• Cardiovascular effects: Cardiovascular effects: Tachycardia, palpitations, premature ventricular complexes, and changes in blood pressure (increases or decreases).
• Neuromuscular effects: Neuromuscular effects: Skeletal muscle tremors and twitching.
• CNS stimulation: CNS stimulation: Nervousness, excitement, restlessness, dizziness, or anxiety.
• Metabolic effects: Metabolic effects: Transient hypokalemia due to intracellular potassium shift; potassium supplementation is rarely required.
• Gastrointestinal signs: Gastrointestinal signs: Vomiting or decreased appetite, especially with oral formulations.
• Cats: Cats: The S-isomer of albuterol may increase airway inflammation; racemic albuterol should be limited to acute rescue use rather than long-term therapy.

Overdose

Significant toxicity may occur following oral overdose or when animals (especially dogs) bite or puncture metered-dose inhalers, resulting in rapid systemic absorption.

• Cardiovascular toxicity: Cardiovascular toxicity: Tachycardia, hypertension, cardiac arrhythmias, QT interval prolongation, and myocardial excitability.
• CNS effects: CNS effects: Tremors, agitation, hyperexcitability, lethargy, mydriasis, and seizures in severe cases.
• Respiratory signs: Respiratory signs: Panting or tachypnea.
• Gastrointestinal signs: Gastrointestinal signs: Vomiting and diarrhea.
• Dogs: Dogs: Most reported overdoses occur from inhaler puncture (chewing/piercing). Onset of signs: 1-3 hours. Aretrospective of 501 dogs: 94% developed clinical signs (6% subclinical). Most common signs: tachycardia 81%, tachypnea 33%, depression 21%, vomiting 19%. Hypokalemia 21%, arrhythmias 3.4%, mortality 0.4% (2 of 501 dogs). One published case of acute nontraumatic rhabdomyolysis in a greyhound after albuterol toxicosis.
• Management:Management: Inpatient supportive care. Beta-blockers (propranolol or esmolol IV) for significant tachyarrhythmias —501-dog study reports 40% required a beta-blocker. Diazepam for tremors or CNS excitation. For ventricular arrhythmias . lidocaine in dogs 2-4 mg/kg IV slow (max 8 mg/kg over 1-2 min) followed by CRI 25-100 µg/kg/min; in cats 0.25-0.5 mg/kg IV very slowly (cats have predilection for CNS and CV toxicity from lidocaine — extreme caution). Treat hypophosphatemia (<1 mg/dL) with potassium phosphate 0.01-0.03 mM/kg/h IV . Decontamination is generally ineffective for inhaler ingestion; tablet ingestion in asymptomatic patients can be managed like any oral overdose. Consult a 24-hour veterinary poison control centre for confirmed or suspected overdoses.
• Potassium supplementation: Potassium supplementation: May be required but should be administered cautiously due to the risk of rebound hyperkalemia.

Key Notes

Practical clinical considerations to optimize the safe and effective use of albuterol in veterinary patients:

• Rescue medication: Rescue medication: Albuterol is best reserved for acute relief of bronchospasm and should not be relied upon as sole long-term therapy, especially in cats with asthma.
• Inhalation preference: Inhalation preference: Inhaled formulations provide rapid bronchodilation with minimal systemic exposure compared to oral administration.
• Species variability: Species variability: Clinical response and tolerance vary considerably between species (cats, dogs), requiring species-specific dosing and monitoring.
• Short duration of action: Short duration of action: Bronchodilatory effects are relatively brief, particularly in horses, necessitating repeat dosing or adjunctive therapy.
• Inflammation control: Inflammation control: Persistent or frequent need for albuterol often indicates inadequate control of underlying airway inflammation.
• Handling of inhalers: Handling of inhalers: Metered-dose inhalers should be stored and handled carefully to prevent accidental puncture or exposure.
• Administration technique: Administration technique: Proper use of spacers and masks improves drug delivery and reduces stress, particularly in cats.
• Performance animals: Performance animals: Use in competition animals may be restricted; regulatory rules should be reviewed prior to administration.